Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor used to treat B-cell malignancies like mantle cell lymphoma and chronic lymphocytic leukemia. It interferes with B-cell receptor signaling, inhibiting cancer cell proliferation. It is considered to have fewer off-target effects than ibrutinib. It is taken orally.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Acalabrutinib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Acalabrutinib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Acalabrutinib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
